JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback